
Emergent BioSolutions is planning a major expansion of manufacturing capacity for its anthrax vaccine BioThrax to meet the biodefense objectives …

GlaxoSmithKline, Novartis and Emergent BioSolutions will share a $400 million contract from the US government to provide vaccine manufacturing capacity …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

